In the whole cohort, high p53 expression was associated with a poorer outcome in terms of shorter breast cancer-specific survival (BCSS) (p = 0.006) (Figure 2B) but not in ER+(Figure 2C) or ER- tumours (Figure 2D). This evidence concerns the gene TP53 and neoplasm.